Inhibition of toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury

Circulation

Volumn 114, Issue SUPPL. 1, 2006, Pages

  Shimamoto, Akira ^a   Chong, Albert J ^b   Yada, Masaki ^a   Shomura, Shin ^b   Takayama, Hiroo ^b   Fleisig, Ani J ^b   Agnew, Matthew L ^b   Hampton, Craig R ^b   Rothnie, Christine L ^b   Spring, Denise J ^b   Pohlman, Timothy H ^b   Shimpo, Hideto ^a   Verrier, Edward D ^b  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Ischemia; Myocardial infarction; Reperfusion; Signal transduction

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; ERITORAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECEPTOR BLOCKING AGENT; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG; 3 O DECYL 2 DEOXY 6 O (2 DEOXY 3 O (3 METHOXYDECYL) 6 O METHYL 2 ((1 OXO 11 OCTADECENYL)AMINO) 4 O PHOSPHONOGLUCOPYRANOSYL) 2 ((1,3 DIOXOTETRADECYL)AMINO) 1 (DIHYDROXY PHOSPHATE)GLUCOPYRANOSE; 3-O-DECYL-2-DEOXY-6-O-(2-DEOXY-3-O-(3-METHOXYDECYL)-6-O-METHYL-2-((1-OXO-11-OCTADECENYL)AMINO)-4-O-PHOSPHONOGLUCOPYRANOSYL)-2-((1,3-DIOXOTETRADECYL)AMINO)-1-(DIHYDROXY PHOSPHATE)GLUCOPYRANOSE; DISACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; SUGAR PHOSPHATE; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; ASSAY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; INFLAMMATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION; REPERFUSION INJURY; RIBONUCLEASE PROTECTION ASSAY; STAINING; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING;

ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; DISACCHARIDES; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; INFLAMMATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NF-KAPPA B; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SUGAR PHOSPHATES; TOLL-LIKE RECEPTOR 4;

EID: 33747178729     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.000901     Document Type: Article

References (24)

1. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol. 1995;146:419-428.
2. Moukarbel GV, Ayoub CM, Abchee AB. Pharmacological therapy for myocardial reperfusion injury. Curr Opin Pharmacol. 2004;4:147-153.
3. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394-397.
4. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085-2088.
5. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg. 2004;128:170-179.
6. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, Rossignol DP. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther. 2003;304:1093-1102.
7. Triantafilou M, Triantafilou K. Heat-shock protein 70 and heat-shock protein 90 associate with Toll-like receptor 4 in response to bacterial lipopolysaccharide. Biochem Soc Trans. 2004;32:636-639.
8. Schuster JM, Nelson PS. Toll receptors: an expanding role in our understanding of human disease. J Leukoc Biol. 2000;67:767-773.
9. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104:271-280.
10. Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004;16:3-9.
11. Wong YN, Rossignol D, Rose JR, Kao R, Carter A, Lynn M. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol. 2003;43:735-742.
12. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000;164:558-561.
13. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson MA, Calderwood SK. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem. 2002;277:15028-15034.
14. Vabulas RM, Braedel S, Hilf N, Singh-Jasuja H, Herter S, Ahmad-Nejad P, Kirschning CJ, Da Costa C, Rammensee HG, Wagner H, Schild H. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem. 2002;277:20847-20853.
15. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol. 2004;76:514-519.
16. Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL, Browder W, Williams DL. Modulating Toll-like receptor mediated signaling by (1->3)-beta-D-glucan rapidly induces cardioprotection. Cardiovasc Res. 2004;61:538-547.
17. Williams DL, Ha T, Li C, Laffan J, Kalbfleisch J, Browder W. Inhibition of LPS-induced NFkappaB activation by a glucan ligand involves down-regulation of IKKbeta kinase activity and altered phosphorylation and degradation of IkappaBalpha. Shock. 2000;13:446-452.
18. Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, Knaus UG. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol. 2000;1:533-540.
19. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001;104:330-335.
20. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996;87:13-20.
21. de Kleijn D, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res. 2003;60:58-67.
22. Altavilla D, Deodato B, Campo GM, Arlotta M, Miano M, Squadrito G, Saitta A, Cucinotta D, Ceccarelli S, Ferlito M, Tringali M, Minutoli L, Caputi AP, Squadrito F. IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-kappaB and reduces the inflammatory response in myocardial ischemia-reperfusion injury. Cardiovasc Res. 2000;47:515-528.
23. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med. 1997;3:894-899.
24. Morgan EN, Boyle EM, Jr., Yun W, Griscavage-Ennis JM, Farr AL, Canty TG, Jr., Pohlman TH, Verrier ED. An essential role for NF-kappaB in the cardioadaptive response to ischemia. Ann Thorac Surg. 1999;68:377-382.